

Prior Authorization Annual Review of Glumetza™ and Fortamet® FY'08

Oklahoma Health Care Authority
February 2009

Category Criteria for FY'08

Approval will be based on clinical documentation of inability to take other forms of generic metformin ER - after slow titration of 500 mg ER at 2 week intervals up to 2000 mg daily.

Product Info:

Both have an FDA Therapeutic Equivalence Code of BX and are presumed to be therapeutically **inequivalent** to other extended release metformin products currently available.

Utilization

For the 2008 fiscal year, 6,729 members received metformin products through the *SoonerCare* program.


BRAND NAME	CLAIMS	UNITS	DAYS	MEMBERS	COST	UNITS/ DAY	COST/ DAY
METFORMIN TAB 500MG	17,137	1,290,117	574,901	4,403	\$ 156,517.14	2.24	\$0.27
METFORMIN TAB 1000MG	8,948	612,883	312,201	2,087	\$ 94,565.44	1.96	\$0.30
METFORMIN TAB 500MG ER	2,052	164,790	72,291	557	\$ 23,556.97	2.28	\$0.33
METFORMIN TAB 850MG	1,659	118,446	56,252	413	\$ 20,748.93	2.11	\$0.37
METFORMIN TAB 750MG ER	176	10,426	7,381	61	\$ 2,928.20	1.41	\$0.40
FORTAMET TAB 1000MG	16	630	630	2	\$ 2,149.18	1	\$3.41
FORTAMET TAB 500MG	3	270	90	1	\$ 431.98	3	\$4.80
RIOMET SOL	48	21,211	1,468	18	\$ 3,610.80	14.45	\$2.46
GLUCOPHAGE TAB 1000MG	23	1,507	618	2	\$ 2,848.45	2.44	\$4.61
GLUCOPHAGE TAB XR 500MG	22	2,540	635	2	\$ 2,468.13	4	\$3.89
GLUMETZA TAB 500MG	9	600	275	3	\$ 709.66	2.18	\$2.58
GLUCOPHAGE TAB 500MG	5	500	250	1	\$ 472.26	2	\$1.89
Totals	30,098	2,223,920	1,026,992		\$311,007.14	2.17	\$0.30

Fiscal Year	Total Members	Total Claims	Total Cost	Cost per Claim	Cost per Day	Total Days
2007	6,017	27,690	\$256,589.44	\$9.27	\$0.28	917,829
2008	6,729	30,098	\$311,007.14	\$10.33	\$0.30	1,026,992
Percent Change	11.8%	8.7%	21.2%	11.4%	7.1%	11.9%

Total petitions received for Fortamet®/Glumetza™ during specified time period: 35

Approved 8
 Denied 14
 Incomplete 13

Age and Gender



Market Update

December, 2008- Generex Biotechnology Corporation announces positive results of metformin chewing gum trial (MetControl™). Currently in phase 2 trials.

Recommendations

The College of Pharmacy recommends continuation of current coverage for Fortamet® and Glumetza™.